HYALGAN

This brand name is authorized in Austria, Cyprus, Ecuador, Spain, France, Hong Kong, Lithuania, Poland, Romania, Singapore, Tunisia

Active ingredients

The drug HYALGAN contains one active pharmaceutical ingredient (API):

1 Hyaluronate sodium UNII YSE9PPT4TH - HYALURONATE SODIUM

Read about Hyaluronate sodium

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HYALGAN Solution for injection	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M09AX01	Hyaluronic acid	M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 1224-MEE-0815
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 262IS14F12, 63006
Country: FR	Base de données publique des médicaments	Identifier(s): 64052038
Country: HK	Department of Health Drug Office	Identifier(s): 34494
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1012010, 1071036, 1081002, 1091322
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100029680, 100290408, 100376334, 100406443, 100412350, 100415962, 100437194, 100447755
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67509001, W67509002, W67510001
Country: SG	Health Sciences Authority	Identifier(s): 06242P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 7883012